Chelsea Therapeutics' (CHTP) Northera Met Primary Endpoint In Phase III Trial
Tweet Send to a Friend
Up)
Chelsea Therapeutics (Nasdaq: CHTP) announced that preliminary analyses of its Phase III NORTHERA Study 301 met its primary endpoint.
Northera provided clinically meaningful and statistically significant improvement (p=0.003) in symptoms associated with neurogenic orthostatic hypotension.
Northera was also both safe and very well tolerated.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Northera provided clinically meaningful and statistically significant improvement (p=0.003) in symptoms associated with neurogenic orthostatic hypotension.
Northera was also both safe and very well tolerated.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Chelsea Therapeutics to Present at the 38th Annual Deutsche Bank Health Care Conference
- Rigel Pharma (RIGL) Advances R348 to Phase 2
- Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
